NCT06887556 Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
| NCT ID | NCT06887556 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Birmingham |
| Condition | Mpox |
| Study Type | INTERVENTIONAL |
| Enrollment | 650 participants |
| Start Date | 2025-02-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 650 participants in total. It began in 2025-02-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.
Eligibility Criteria
Inclusion Criteria: * Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements. * Group 1 (suspected exposure cohort) only * Live within or adjacent to an epidemiologically identified region of Mpox transmission * Close contacts of those with microbiologically confirmed Mpox * Group 2 (post-exposure/vaccinated cohort) only * Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox/MVA vaccine * Fully recovered from Mpox infection * Group 3 (control cohort) only: * Asymptomatic with no known exposure to Mpox Exclusion Criteria: * Unwilling or unable to provide informed consent to take part * Unwilling or unable to comply with study procedures * History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study * Have a bleeding disorder deemed significant by a member of the study team * Pregnant or breast-feeding females * Group 1 (suspected exposure cohort) only * Known history of Mpox infection * Current symptoms consistent with Mpox * Known exposure to Mpox in the last month * Group 2 (post-exposure/vaccinated cohort) only * Participants with any ongoing symptoms of Mpox, indicating incomplete recovery. * Group 3 (control cohort only) * Symptoms of Mpox * Known exposure to Mpox in the last month
Contact & Investigator
Christopher Green
PRINCIPAL INVESTIGATOR
University of Birmingham
Frequently Asked Questions
Who can join the NCT06887556 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 80 Years, studying Mpox. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06887556 currently recruiting?
Yes, NCT06887556 is actively recruiting participants. Contact the research team at h.shema@cleancooling.org for enrollment information.
Where is the NCT06887556 trial being conducted?
This trial is being conducted at Kigali, Rwanda.
Who is sponsoring the NCT06887556 clinical trial?
NCT06887556 is sponsored by University of Birmingham. The principal investigator is Christopher Green at University of Birmingham. The trial plans to enroll 650 participants.